# Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC

> **NCT05244213** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 35 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- EGFR Activating Mutation

## Interventions

- **BIOLOGICAL:** Sintilimab
- **DRUG:** Carboplatin
- **DRUG:** Nab paclitaxel

## Key facts

- **NCT ID:** NCT05244213
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-04
- **Primary completion:** 2024-06-05
- **Final completion:** 2025-12-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2024-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05244213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05244213, "Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05244213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*